Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | +3.64% | +2.70% | -35.96% |
May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 74.06M | Sales 2025 * | 127M | Capitalization | 83.58M |
---|---|---|---|---|---|
Net income 2024 * | 17M | Net income 2025 * | 70M | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
5.43
x | P/E ratio 2025 * |
1.41
x | Employees | 208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.27% |
Latest transcript on Protalix BioTherapeutics, Inc.
1 day | +3.64% | ||
1 week | +2.70% | ||
1 month | -3.39% | ||
3 months | -19.72% | ||
6 months | -15.56% | ||
Current year | -35.96% |
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.39% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 1.14 | +3.64% | 392,268 |
24-05-10 | 1.1 | -12.00% | 2,178,207 |
24-05-09 | 1.25 | +9.65% | 823,118 |
24-05-08 | 1.14 | 0.00% | 286,011 |
24-05-07 | 1.14 | +2.70% | 225,755 |
Delayed Quote Nyse, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.96% | 80.65M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- PLX Stock